FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4363677046> ?p ?o ?g. }

• W4363677046 endingPage "8" @default.
• W4363677046 startingPage "1" @default.
• W4363677046 abstract "To assess the use of cytotoxic drugs as first-line chemotherapy for nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutation.This study uses the network meta-analysis (NMA) method, with the inclusion of prospective randomized control studies related to the treatment of EGFR-positive nonsquamous NSCLC, to compare the efficacy of various EGFR-TKIs. As of September 4, 2022, 16 studies on a total of 4180 patients were included. The retrieved literature was comprehensively evaluated as per the established inclusion and exclusion criteria, and valid data were extracted and included for analysis.The 6 treatment regimens included cetuximab, CTX (cyclophosphamide), icotinib, gefitinib, afatinib, and erlotinib. All of the 16 studies reported their findings about overall survival (OS), and 15 of them also reported findings about progression-free survival (PFS). The NMA results showed that there was no significant difference in OS among the 6 treatment regimens. It was observed that erlotinib had the highest likelihood of obtaining the best OS, followed by afatinib, gefitinib, icotinib, CTX, and cetuximab, in descending order. This indicates that the highest possibility of achieving the best OS was with erlotinib, while the lowest was with cetuximab. The NMA results also showed that the PFS achieved with treatment using afatinib, erlotinib, and gefitinib were all higher than that with treatment using CTX, with statistically significant differences. The results showed that there was no significant difference in PFS among erlotinib, gefitinib, afatinib, cetuximab, and icotinib. CTX, cetuximab, icotinib, gefitinib, afatinib, and erlotinib were ranked in descending order based on the PFS indicator SUCRA values, which implied that erlotinib had the highest possibility in achieving the best PFS, while CTX had the lowest. Discussion. EGFR-TKIs must be carefully selected for the treatment of different histologic subtypes of NSCLC. For EGFR mutation (+) nonsquamous NSCLC, erlotinib is most likely to achieve the best OS and PFS, which makes it the first choice in the formulation of a treatment plan." @default.
• W4363677046 created "2023-04-11" @default.
• W4363677046 creator A5002910259 @default.
• W4363677046 creator A5014068004 @default.
• W4363677046 creator A5019595634 @default.
• W4363677046 creator A5068865065 @default.
• W4363677046 creator A5077181770 @default.
• W4363677046 creator A5087592842 @default.
• W4363677046 date "2023-04-10" @default.
• W4363677046 modified "2023-09-26" @default.
• W4363677046 title "The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis" @default.
• W4363677046 cites W1969116196 @default.
• W4363677046 cites W1980497534 @default.
• W4363677046 cites W2081348199 @default.
• W4363677046 cites W2096198395 @default.
• W4363677046 cites W2111662961 @default.
• W4363677046 cites W2112660136 @default.
• W4363677046 cites W2124967121 @default.
• W4363677046 cites W2128278369 @default.
• W4363677046 cites W2129360604 @default.
• W4363677046 cites W2132157071 @default.
• W4363677046 cites W2133149289 @default.
• W4363677046 cites W2137043950 @default.
• W4363677046 cites W2154662831 @default.
• W4363677046 cites W2166084034 @default.
• W4363677046 cites W2168340462 @default.
• W4363677046 cites W2171139285 @default.
• W4363677046 cites W2534193912 @default.
• W4363677046 cites W2561565091 @default.
• W4363677046 cites W2594980227 @default.
• W4363677046 cites W2608495247 @default.
• W4363677046 cites W2619919786 @default.
• W4363677046 cites W2747505649 @default.
• W4363677046 cites W2790649727 @default.
• W4363677046 cites W2792821195 @default.
• W4363677046 cites W2806221342 @default.
• W4363677046 cites W2922022182 @default.
• W4363677046 cites W2937704370 @default.
• W4363677046 cites W2964471257 @default.
• W4363677046 cites W3010387843 @default.
• W4363677046 cites W3014582110 @default.
• W4363677046 cites W3091054691 @default.
• W4363677046 cites W3094019790 @default.
• W4363677046 cites W3102922803 @default.
• W4363677046 cites W3113022089 @default.
• W4363677046 cites W3178692152 @default.
• W4363677046 cites W4376454014 @default.
• W4363677046 doi "https://doi.org/10.1155/2023/5272125" @default.
• W4363677046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37077340" @default.
• W4363677046 hasPublicationYear "2023" @default.
• W4363677046 type Work @default.
• W4363677046 citedByCount "1" @default.
• W4363677046 countsByYear W43636770462023 @default.
• W4363677046 crossrefType "journal-article" @default.
• W4363677046 hasAuthorship W4363677046A5002910259 @default.
• W4363677046 hasAuthorship W4363677046A5014068004 @default.
• W4363677046 hasAuthorship W4363677046A5019595634 @default.
• W4363677046 hasAuthorship W4363677046A5068865065 @default.
• W4363677046 hasAuthorship W4363677046A5077181770 @default.
• W4363677046 hasAuthorship W4363677046A5087592842 @default.
• W4363677046 hasBestOaLocation W43636770461 @default.
• W4363677046 hasConcept C121608353 @default.
• W4363677046 hasConcept C126322002 @default.
• W4363677046 hasConcept C143998085 @default.
• W4363677046 hasConcept C2776256026 @default.
• W4363677046 hasConcept C2778087573 @default.
• W4363677046 hasConcept C2779438470 @default.
• W4363677046 hasConcept C2779998722 @default.
• W4363677046 hasConcept C2780580887 @default.
• W4363677046 hasConcept C2780586478 @default.
• W4363677046 hasConcept C2909325608 @default.
• W4363677046 hasConcept C526805850 @default.
• W4363677046 hasConcept C71924100 @default.
• W4363677046 hasConceptScore W4363677046C121608353 @default.
• W4363677046 hasConceptScore W4363677046C126322002 @default.
• W4363677046 hasConceptScore W4363677046C143998085 @default.
• W4363677046 hasConceptScore W4363677046C2776256026 @default.
• W4363677046 hasConceptScore W4363677046C2778087573 @default.
• W4363677046 hasConceptScore W4363677046C2779438470 @default.
• W4363677046 hasConceptScore W4363677046C2779998722 @default.
• W4363677046 hasConceptScore W4363677046C2780580887 @default.
• W4363677046 hasConceptScore W4363677046C2780586478 @default.
• W4363677046 hasConceptScore W4363677046C2909325608 @default.
• W4363677046 hasConceptScore W4363677046C526805850 @default.
• W4363677046 hasConceptScore W4363677046C71924100 @default.
• W4363677046 hasLocation W43636770461 @default.
• W4363677046 hasLocation W43636770462 @default.
• W4363677046 hasLocation W43636770463 @default.
• W4363677046 hasOpenAccess W4363677046 @default.
• W4363677046 hasPrimaryLocation W43636770461 @default.
• W4363677046 hasRelatedWork W1480640671 @default.
• W4363677046 hasRelatedWork W1601037103 @default.
• W4363677046 hasRelatedWork W2186047679 @default.
• W4363677046 hasRelatedWork W2332684061 @default.
• W4363677046 hasRelatedWork W2542769082 @default.
• W4363677046 hasRelatedWork W2979585789 @default.
• W4363677046 hasRelatedWork W3000070469 @default.
• W4363677046 hasRelatedWork W4281670385 @default.

• next